MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of ...
Hosted on MSN

Pooled cord blood transplants achieve near-perfect results in early trial

Stem cell transplants for acute leukemia using pooled, non-human leukocyte antigen (HLA)-matched cord blood led to near-perfect engraftment and no severe graft-versus-host disease (GVHD) in a small ...
Fred Hutch

How chronic graft-versus-host disease unfolds ten years after transplant

Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...
Healio

Novel cord blood transplant approach confers ‘remarkable’ outcomes in high-risk leukemia

The addition of an off-the-shelf pooled stem cell product to a single unit of umbilical cord blood conferred favorable ...
Healio

Many patients disagree with clinicians’ assessments of their graft-versus-host disease

Please provide your email address to receive an email when new articles are posted on . Over 65% of patient-reported treatment responses agreed with clinicians’ evaluations, whereas 34.4% did not.